These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 18056944)
1. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Greene RE; Mauskopf J; Roberts CS; Zyczynski T; Schlamm HT Am J Health Syst Pharm; 2007 Dec; 64(24):2561-8. PubMed ID: 18056944 [TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A Value Health; 2006; 9(1):12-23. PubMed ID: 16441520 [TBL] [Abstract][Full Text] [Related]
3. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand? Garbino J; Schnetzler G; Roberts C Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Jansen JP; Meis JF; Blijlevens NM; van't Wout JW Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893 [TBL] [Abstract][Full Text] [Related]
5. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501 [TBL] [Abstract][Full Text] [Related]
7. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146 [TBL] [Abstract][Full Text] [Related]
10. Voriconazole treatment of invasive aspergillosis: real-world versus health-economic model results. Van Campenhout H; Marbaix S; Derde MP; Annemans L Clin Drug Investig; 2008; 28(8):509-21. PubMed ID: 18598097 [TBL] [Abstract][Full Text] [Related]
11. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B; N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683 [TBL] [Abstract][Full Text] [Related]
12. Economic effects of aspergillosis management in high-risk patients. Leather H Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762 [TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic assessment of therapy for invasive aspergillosis. Luong ML; Husain S; Rotstein C Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. Al-Badriyeh D; Liew D; Stewart K; Kong DC J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. Selleslag D; Vogelaers D; Marbaix S Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. Chandrasekar PH; Cutright J; Manavathu E J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091 [TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414 [TBL] [Abstract][Full Text] [Related]
18. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. Ostermann H; Solano C; Jarque I; Garcia-Vidal C; Gao X; Barrueta JA; De Salas-Cansado M; Stephens J; Xue M; Weber B; Charbonneau C BMC Pharmacol Toxicol; 2014 Sep; 15():52. PubMed ID: 25253630 [TBL] [Abstract][Full Text] [Related]
19. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. Wieland T; Liebold A; Jagiello M; Retzl G; Birnbaum DE J Heart Lung Transplant; 2005 Jan; 24(1):102-4. PubMed ID: 15653389 [TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]